Journal of Hepatology
Volume 44, Issue 1 , Pages 19-23 , January 2006

Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?

References 

  1. Nalesnik MA, Starzl TE. Epstein–Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transpl Sci. 1994;4:61–79
  2. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3:79–87
  3. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein–Barr Virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517–1525
  4. Larson RS, Scott MA, McCurley TL, Vnencak-Jones CL. Microsatellite analysis of posttransplant lymphoproliferative disorders: determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res. 1996;56:4378–4481
  5. Smets F, Sokal EM. Epstein–Baar virus-related lymphoproliferation in children after liver transplantation: role of immunity, diagnosis, and management. Pediatr Transplant. 2002;280–287
  6. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, et al. Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus and immunosuppression. Transplantation. 1996;62:370–375
  7. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236:429–437
  8. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033–1036
  9. Domingo-Domenech E, de Sanjose S, Gonzalez-Barca E, Romagosa V, Domingo-Claros A, Gil-Vernet S, et al. : Post-transplant lymphomas: a 20-year epidemiologic, clinical and pathologic study in a single center. Haematologica. 2001;86:715–721
  10. Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, et al. Early signs and risk factors for the increased incidence of Epstein–Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation. 1997;64:1438–1442
  11. Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation. 2001;71:224–229
  12. Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL, et al. Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant. 2004;8:243–248
  13. Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, et al. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppression induction therapy after liver transplantation. Clin Transplant. 1998;12:303–312
  14. Kieff E. Epstein–Barr virus and its replication. In:  Fields BN,  Knipe DM,  Howley PM, editor. Fields virology. Philadelphia, PA: Lippincott-Raven; 1996;p. 2343
  15. Cohen JI. Epstein–Barr virus infection. N Engl J Med. 2000;343:481–492
  16. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE, et al. Early identification of Epstein–Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol. 1995;89:98
  17. Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant. 2002;2:894–895
  18. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002;73:1603–1610
  19. Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, et al. The value of prospective monitoring of Epstein–Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis. 2004;6:15–22
  20. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72:1012–1019
  21. Armes JE, Angus P, Southey MC, Battaglia SE, Ross BC, Jones RM, et al. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation. Cancer. 1994;74:2436–2441
  22. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, et al. Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity?. J Clin Oncol. 1998;16:2052–2059
  23. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation. 2005;79:244–247
  24. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein Barr virus negative post-transplant lymphoproliferative disorders: a distinct entity?. Am J Surg Pathol. 2001;25:324–330
  25. Finn L, Reyes J, Bueno J, Yunis E. Epstein–Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol. 1998;22:299–309
  26. Michaelis S, Kazakov DV, Schmid M, Dummer R, Burg G, Kempf W. Hepatitis C and G viruses in B-cell lymphomas of the skin. J Cutan Pathol. 2003;30:369–372
  27. Starkebaum G, Sasso EH. Hepatitis C and B cells: induction of autoimmunity and lymphoproliferation may reflect chronic stimulation through cell-surface receptors. J Rheumatol. 2004;31:416–418
  28. Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica. 2004;89:70–76
  29. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective. Hepatology. 1997;26:1375–1379
  30. Hezode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology. 1999;30:775–778
  31. Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood. 2003;102:1196–1201
  32. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938–941
  33. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–1353
  34. Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study: the University of Pittsburgh PTLD Study Group. Leuk Lymphoma. 1999;36:109
  35. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1999;131:98
  36. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hezode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation. 2002;74:1103–1109
  37. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583–587
  38. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005;46:191–196
  39. Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, et al. Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant. 2003;3:1369–1377
  40. Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol. 2004;38:360–363

PII: S0168-8278(05)00674-4

doi: 10.1016/j.jhep.2005.10.008

Journal of Hepatology
Volume 44, Issue 1 , Pages 19-23 , January 2006

Article Tools

* Image Usage & Resolution